CRISPR-Cas12a for Highly Efficient and Marker-Free Targeted Integration in Human Pluripotent Stem Cells

Author:

Hammad Ruba1234,Alzubi Jamal12ORCID,Rhiel Manuel12ORCID,Chmielewski Kay O.124,Mosti Laura12ORCID,Rositzka Julia12,Heugel Marcel12,Lawrenz Jan12ORCID,Pennucci Valentina12,Gläser Birgitta5ORCID,Fischer Judith56ORCID,Schambach Axel78,Moritz Thomas78,Lachmann Nico89101112ORCID,Cornu Tatjana I.126ORCID,Mussolino Claudio126,Schäfer Richard1236,Cathomen Toni126ORCID

Affiliation:

1. Institute for Transfusion Medicine and Gene Therapy, Medical Center—University of Freiburg, 79106 Freiburg, Germany

2. Center for Chronic Immunodeficiency (CCI), Medical Center—University of Freiburg, 79106 Freiburg, Germany

3. Freiburg iPS Core Facility, Medical Center—University of Freiburg, 79106 Freiburg, Germany

4. PhD Program, Faculty of Biology, University of Freiburg, 79104 Freiburg, Germany

5. Institute of Human Genetics, Medical Center—University of Freiburg, 79106 Freiburg, Germany

6. Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany

7. Institute for Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany

8. REBIRTH Center for Regenerative and Translational Medicine, Hannover Medical School, 30625 Hannover, Germany

9. Department of Pediatric Pulmonology, Allergology and Neonatology, Hannover Medical School, 30625 Hannover, Germany

10. Biomedical Research in Endstage and Obstructive Lung Disease, German Center for Lung Research, Hannover Medical School, 30625 Hannover, Germany

11. Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, 30625 Hannover, Germany

12. Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), 30625 Hannover, Germany

Abstract

The CRISPR-Cas12a platform has attracted interest in the genome editing community because the prototypical Acidaminococcus Cas12a generates a staggered DNA double-strand break upon binding to an AT-rich protospacer-adjacent motif (PAM, 5′-TTTV). The broad application of the platform in primary human cells was enabled by the development of an engineered version of the natural Cas12a protein, called Cas12a Ultra. In this study, we confirmed that CRISPR-Cas12a Ultra ribonucleoprotein complexes enabled allelic gene disruption frequencies of over 90% at multiple target sites in human T cells, hematopoietic stem and progenitor cells (HSPCs), and induced pluripotent stem cells (iPSCs). In addition, we demonstrated, for the first time, the efficient knock-in potential of the platform in human iPSCs and achieved targeted integration of a GFP marker gene into the AAVS1 safe harbor site and a CSF2RA super-exon into CSF2RA in up to 90% of alleles without selection. Clonal analysis revealed bi-allelic integration in >50% of the screened iPSC clones without compromising their pluripotency and genomic integrity. Thus, in combination with the adeno-associated virus vector system, CRISPR-Cas12a Ultra provides a highly efficient genome editing platform for performing targeted knock-ins in human iPSCs.

Funder

German Federal Ministry of Education and Research

Open Access Publication Fund of the University of Freiburg, Germany

Publisher

MDPI AG

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3